Table 1.
Baseline demographics and clinical characteristics
| Characteristic | Value (n=45) |
|---|---|
| Sex | |
| Male | 29 (64.4) |
| Female | 16 (35.6) |
| Age (yr) | 54 (35–62) |
| Isotype | |
| IgG | 29 (64.4) |
| IgA | 9 (20.0) |
| Light chain only | 7 (15.6) |
| Kappa | 31 (68.9) |
| Lambda | 14 (31.1) |
| ISS stage | |
| I | 13 (28.9) |
| II | 21 (46.7) |
| III | 11 (24.4) |
| Albumin (g/L) | 3.4 (2.2–5.5) |
| β 2-microglobulin (mg/L) | 3.44 (1.97–19.5) |
| Plasmacytoma | 8 (17.8) |
| Bone marrow, plasma cell (%) | 43.5 (2–99) |
| Serum monoclonal protein (g/dL) | 4.59 (0–27.3) |
| 24-Hour urine monoclonal protein (mg/day) | 29.7 (0–6,789) |
| Karyotype | |
| Normal | 35 (77.8) |
| Abnormal | 10 (22.2) |
| FISH analysis | |
| del13q | 4/23 (17.4) |
| del17p | 1/22 (4.5) |
| t (4;14) | 4/22 (18.2) |
| t (14;16) | 0/19 (0) |
| t (11;14) | 4/19 (8.9) |
| Standard risk | 19/24 (79.2) |
| High riska) | 5/24 (20.8) |
| Induction regimen | |
| TD | 23 (51.1) |
| VTD | 19 (42.2) |
| VMP | 1 (2.2) |
| CTD | 1 (2.2) |
| VCD | 1 (2.2) |
| Mobilization for ASCT | |
| G-CSF only | 21 (46.7) |
| G-CSF with chemotherapy | 24 (53.3) |
| Conditioning for ASCT | |
| MEL200 | 35 (77.8) |
| MEL140 | 1 (2.2) |
| BUMEL | 1 (2.2) |
| BUTHIO | 8 (17.8) |
Values are presented as number (%) or median (range). ASCT, autologous stem cell transplantation; BUMEL, busulfan and melphalan; BUTHIO, busulfan, and thiotepa; CTD, cyclophosphamide, thalidomide, dexamethasone; FISH, fluorescent in situ hybridization; G-CSF, granulocyte-colony stimulating factor; ISS, International Staging System; MEL, melphalan; TD, thalidomide and dexamethasone; VCD, bortezomib, cyclophosphamide, dexamethasone; VMP, bortezomib, melphalan, prednisone; VTD, bortezomib, thalidomide, and dexamethasone.
a)
Defined as del17p or t(4;14) or t(14;16).